Lab
Cellum Biomedical INC.
Cellum Biomedical INC. was paid $1.74M by Medicaid between Oct 2020 and Oct 2024, across 5 billing codes. Its largest line is U0004, 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r — 76% of everything it billed.
33Billing provider infoCELLUM BIOMEDICAL INC.
TEMECULA, CA 92592
TEMECULA, CA 92592
33aNPI1912522723assigned 06/08/2020
33bProvider typeClinical Medical Laboratory
28Total paid$1.74M
24GClaims38,415
24DCodes billed5
24AFirst – last monthOct 2020 – Oct 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in California
Rank by total paid#153 of 561
Median peer was paid$222K
This provider vs. median7.8×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2020 | 1,450 | $85K | |
| 2021 | 9,524 | $432K | |
| 2022 | 20,527 | $930K | |
| 2023 | 5,509 | $246K | |
| 2024incomplete | 1,405 | $46K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 76% | 19,221 | 6,155 | $1.31M |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a snf or by a laboratory on behalf of a hha, any specimen source | 17% | 13,520 | 4,406 | $293K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 5.7% | 2,886 | 1,257 | $99K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 1.4% | 580 | 250 | $25K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 2,208 | 763 | $10K |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialLUCKEY, ELAINE (QA DIRECTOR)